Halozyme TherapeuticsMEX:HALO 87 EV-to-FCF is 28.22 as of Jul. 06, 2026, which is 62% above its 10-year median of 17.43. GuruFocus rates MEX:HALO with a GF Score™ of 87/100 and a GF Value™ of MXN1,622.53 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 330 Biotechnology companies, Halozyme Therapeutics ranks worse than 65.15% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Halozyme Therapeutics's Enterprise Value is MXN197,087 Mil.
Halozyme Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN6,985 Mil. Therefore, Halozyme Therapeutics's EV-to-FCF for today is 28.22.
The historical rank and industry rank for Halozyme Therapeutics's EV-to-FCF or its related term are showing as below:
MEX:HALO'
s EV-to-FCF Range Over the Past 10 Years
Min: -261.02 Med: 17.43 Max: 137.92
Current: 29.61
During the past 13 years, the highest EV-to-FCF of Halozyme Therapeutics was 137.92. The lowest was -261.02. And the median was 17.43.
MEX:HALO's EV-to-FCF is ranked worse than 65.15% of 330
companies
in the Biotechnology industry
Industry Median: 16.3
vs MEX:HALO: 29.61
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Halozyme Therapeutics's PE Ratio (TTM) for today is calculated as:
Halozyme Therapeutics's share price for today is MXN1327.00.
Halozyme Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN51.716.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:HALO vs KYMR, IBRX, PRAX: EV-to-FCF Comparison
For the Biotechnology subindustry, Halozyme Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's EV-to-FCF falls into.
Halozyme Therapeutics's current Enterprise Value is MXN197,087 Mil.
Halozyme Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN6,985 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics (MEX:HALO) has a EV-to-FCF of 28.22 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Halozyme Therapeutics and its competitors. This is 62% above median its historical median of 17.43. According to the industry distribution chart, Halozyme Therapeutics ranks #215 out of 330 companies in the Biotechnology industry, placing it in the top 65.2%.
Is Halozyme Therapeutics' EV-to-FCF too high?
Halozyme Therapeutics' current EV-to-FCF of 28.22 is 62% above median its 10-year median of 17.43. The Biotechnology industry median EV-to-FCF is 16.30. Halozyme Therapeutics' value of 28.22 is 73.1% above this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #215 out of 330 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Halozyme Therapeutics has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' EV-to-FCF compare to KYMR and IBRX?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #215 out of 330 companies for EV-to-FCF. This places Halozyme Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 16.30. Halozyme Therapeutics' value of 28.22 is 73.1% above this benchmark. While the company's 10-year median is 17.43 vs. the industry median of 16.30, Halozyme Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.30, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current EV-to-FCF of 28.22 is 73.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current EV-to-FCF is 28.22, which is 62% above median its own 10-year median of 17.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (MEX:HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN1,622.53, compared to a current price of MXN1,327.00 — trading 18.2% below its estimated fair value. The current EV-to-FCF is 28.22, which is 62% above median its 10-year median of 17.43 and 73.1% above the Biotechnology industry median of 16.30. Halozyme Therapeutics' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Halozyme Therapeutics (MEX:HALO), the current EV-to-FCF is 28.22 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (MEX:HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of MXN1,327.00 is trading 18.2% below its estimated GF Value™ of MXN1,622.53.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for MEX:HALO:
EV-to-FCF: 28.22 (62% above median its 10-year median of 17.43)
GF Value™: MXN1,622.53 vs. price of MXN1,327.00 (18.2% below fair value)
Industry Position: 73.1% above the Biotechnology median (#215 of 330)
No single metric tells the full story. See the MEX:HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
87GF Score
Get the complete analysis for MEX:HALO
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:HALO has been successfully added to your 
